

**FOR IMMEDIATE RELEASE**

January 2005

David Karlman  
Chairman and Chief Executive Officer  
American BioHealth Group, LLC  
15721 Bernardo Heights Parkway Suite 151  
San Diego, California 92128  
(ph) 858-675-3600  
(fax) 858-613-0748  
dkarlman@abgpharma.com

**Treating Hearing Loss: New Compounds Show Promise for American BioHealth Group's Development to Treat or Prevent Hearing Loss**

BOZEMAN, MT. and San Diego, CA.—American BioHealth Group (ABG) and TechLink announce the acquisition by American BioHealth Group of another exclusive license to new patented approaches developed by the US Navy and the University at Buffalo, The State University of New York (UB). This exclusive license covers the use of compounds for the treatment and/or prevention of certain hearing disorders and complements ABG's originally licensed technology by adding new synergistic agents to its growing library of promising compounds.

American BioHealth Group specializes in development of hearing disorder drugs in collaboration with various medical and academic institutions. In 2001, ABG was awarded an exclusive license from the US Navy and UB that addresses various hearing disorders. The company introduced The Hearing Pill™ ([www.thehearingpill.com](http://www.thehearingpill.com)) as a direct result of the commercialization of that first license.

Concerning the award of the new license, David Karlman, Chairman and Chief Executive Officer of American BioHealth Group stated, "As American BioHealth Group expands its portfolio of patented technologies, it is fulfilling its mission to become a leader in developing cutting-edge technology that will address hearing related disorders using safe and unique pharmaceutical approaches." The company is nearing completion of an extensive double blind, placebo controlled, 550+ patient clinical trial and is expected to mark an important milestone toward introducing the first pill clinically proven to prevent hearing loss. Other clinical trials are currently underway as well and more are planned in 2005. "Our research plan is robust and we are confident in our direction and choice of compounds. Our partnering relationships with the Office of Naval Research, the Naval Medical Center San Diego, UB, TechLink and others have helped to enable ABG to pursue this exciting path," Karlman said. "We look forward to our continued relationship with these, and the other world class institutions, as we develop novel treatments to this very important area of medicine."

Speaking about the acquired technology, Mark Mugerditchian, President and Chief Operating Officer of American BioHealth Group said, "Our family of intellectual property is exciting. All of our acquired technology is on sound scientific footing having been demonstrated in the laboratory as being excellent candidates for clinical trials."